Two-year trial in older adults
- Reported quantity
- 25 mg orally
- Frequency
- Once daily
- Study duration
- 24 months
IGF-1, body composition and functional endpoints were tracked throughout.
Protocols · Growth Hormone
MK-677: literature-reported ranges
MK-677 is not a peptide but a small-molecule ghrelin receptor agonist, and it has a real multi-year human trial record from its development programme — including a two-year study in older adults.
Read this first
Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.
Compound at a glance
- Class
- Orally active ghrelin mimetic (non-peptide)
- Reported half-life
- Approximately 24 hours
- Routes used in the literature
- Oral
- Also written as
- Ibutamoren
What the published studies reported
Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.
Short-term GH/IGF-1 pharmacology
- Reported quantity
- 10–50 mg
- Frequency
- Once daily, usually evening
- Study duration
- 2–8 weeks
Dose-response across this window is documented in the development literature.
Reconstitution maths
Supplied as a powder or oral solution rather than a lyophilised injectable vial; concentration is stated per millilitre on the certificate.
Open the reconstitution calculatorHow to read these figures
- Fluid retention and reduced insulin sensitivity are consistently reported in the trial literature.
- The compound is a banned substance under WADA rules.
- Oral bioavailability means contamination and identity assays matter as much as purity.
Sources and citations
These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.
- [1]Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults
Nass R, Pezzoli SS, Oliveri MC, et al. · Ann Intern Med · 2008 · PMID 18981485
Healthy older adults were randomized to receive oral MK-677 (ibutamoren) 25 mg once daily for 2 years to evaluate effects on body composition and IGF-1 levels.
View the record - [2]Oral Administration of the Growth Hormone Secretagogue MK-677 Increases Markers of Bone Turnover in Healthy and Functionally Impaired Elderly Adults
Murphy MG, Bach MA, Plotkin D, et al. (MK-677 Study Group) · J Bone Miner Res · 1999 · PMID 10404019
Elderly subjects received oral MK-677 at doses of 25 mg/day for periods ranging from 4 weeks to 1 year to assess GH/IGF-1 axis stimulation and bone turnover markers.
View the record
Search the databases yourself
Read the MK-677 research briefOther growth hormone compounds
AOD-9604hGH fragment 176-191CJC-1295 (no DAC)Tetra-substituted GHRH (1-29) analogueCJC-1295 (no DAC) + IpamorelinGHRH analogue + selective ghrelin-receptor agonist blendCJC-1295 with DACGHRH analogue with albumin-binding drug affinity complex
All research protocolsPeptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.